Biopharma firm Verastem Oncology Q2 net loss widens
Overview
Verastem Q2 2025 net product revenue reaches $2.1 mln post AVMAPKI FAKZYNJA launch
Net loss for Q2 2025 widens to $25.9 mln, driven by increased expenses
Company ends Q2 2025 with $164.3 mln cash, runway into H2 2026
Result Drivers
AVMAPKI FAKZYNJA LAUNCH - Achieved $2.1 mln in net product revenue in first six weeks post-launch, following FDA approval for KRAS-mutated ovarian cancer treatment
INCREASED EXPENSES - Higher R&D and administrative costs linked to clinical advancements and product launch preparations
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$25.93 mln | ||
Q2 Basic EPS | -$0.39 | ||
Q2 Income from Operations | -$43.76 mln | ||
Q2 Operating Expenses | $45.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Verastem Inc is $14.00, about 59.1% above its August 6 closing price of $5.72
Press Release:
